Poolbeg Pharma Share Price (POLB)

Most interesting bit of that rns is the very direct come and get me message re partnering. If the trial goes as hoped then this is going to be hot

@PoolbegPharma will be presenting new data on POLB 001 at EHA Congress 2026

🩺 Title:

“POLB 001, an oral P38 MAPK Inhibitor for the Prevention of Cytokine Release Syndrome”

Focus: The potential for POLB 001 to reduce key drivers of CRS while preserving anti-tumour activity — a hugely important balance in cancer immunotherapy treatment 👀

📆 Saturday, 13 June 2026

⏰ 18:45 – 19:45 CEST

📍 Poster Session 2

With interest in CRS prevention continuing to build, this is another important opportunity for Poolbeg to showcase the potential value of POLB 001 on the global stage 🌍📈

#Biotech #Cancer #Immunotherapy #CRS #Healthcare #Investing

londonstockexchange.com/news-article/P…

🇨🇦 Another important step forward for #POLB as @PoolbegPharma secures a Canadian patent grant covering the use of p38 MAPK inhibitors, including POLB 001, for the prevention of cancer immunotherapy-induced CRS 🔬

This follows Australia earlier this year and further strengthens the growing global IP estate around what could become a hugely important oncology supportive care asset.

With interim TOPICAL trial data expected this summer and international patent applications progressing, the commercial and partnering potential around POLB 001 continues to build 👀

Cancer immunotherapy is transforming treatment outcomes… but managing CRS safely remains a major challenge.

If Poolbeg can help solve that problem, the opportunity here could be significant.

Read the full article below 👇

https://pharmatimes.com/news/poolbeg-secures-canadian-patent-for-polb-001-in-cancer-immunotherapy-induced-crs/

🧬🇨🇦 @PoolbegPharma 𝗦𝗘𝗖𝗨𝗥𝗘𝗦 𝗖𝗔𝗡𝗔𝗗𝗜𝗔𝗡 𝗣𝗔𝗧𝗘𝗡𝗧 𝗙𝗢𝗥 𝗣𝗢𝗟𝗕 𝟬𝟬𝟭 🇨🇦🧬

Another important IP milestone for #POLB 👀

✅ Canadian patent granted for POLB 001 in cancer immunotherapy-induced CRS

✅ Second national grant secured following Australia 🇦🇺

✅ Covers use of ANY p38 MAPK inhibitor for prevention of CRS

✅ Backed by Poolbeg proprietary data 📊

✅ Strengthens global IP portfolio 🌍

✅ Enhances future partnering value 🤝

Remember…

💥 POLB 001 is targeting Cytokine Release Syndrome linked to cancer immunotherapies

💥 Potential to help move treatment from specialist centres into wider hospital settings

💥 Huge commercial opportunity if successful

The Company continues to build a serious moat around POLB 001 🏰🧬

More patents. More protection. More potential value creation. 📈

londonstockexchange.com/news-article/P…

Patent granted in Canada.